| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Sorafenib in advanced hepatocellular carcinoma.
|
N Engl J Med
|
2008
|
54.30
|
|
2
|
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
|
N Engl J Med
|
2011
|
24.32
|
|
3
|
Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.
|
N Engl J Med
|
2011
|
11.93
|
|
4
|
Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study.
|
J Clin Oncol
|
2013
|
3.71
|
|
5
|
Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study.
|
J Clin Oncol
|
2013
|
3.45
|
|
6
|
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial.
|
J Hepatol
|
2012
|
3.04
|
|
7
|
Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial.
|
J Clin Oncol
|
2012
|
2.92
|
|
8
|
Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301).
|
Gut
|
2010
|
2.55
|
|
9
|
Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma.
|
Cancer
|
2011
|
2.07
|
|
10
|
Research reporting standards for radioembolization of hepatic malignancies.
|
J Vasc Interv Radiol
|
2011
|
1.89
|
|
11
|
Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma.
|
Clin Cancer Res
|
2011
|
1.89
|
|
12
|
Adjuvant intra-arterial injection of iodine-131-labeled lipiodol after resection of hepatocellular carcinoma.
|
Hepatology
|
2003
|
1.65
|
|
13
|
First experience of hepatic radioembolization using microspheres labelled with yttrium-90 (TheraSphere): practical aspects concerning its implementation.
|
Eur J Nucl Med Mol Imaging
|
2009
|
1.56
|
|
14
|
Adjuvant intraarterial injection of 131I-labeled lipiodol after resection of hepatocellular carcinoma: progress report of a case-control study with a 5-year minimal follow-up.
|
J Nucl Med
|
2008
|
1.49
|
|
15
|
Dosimetry based on 99mTc-macroaggregated albumin SPECT/CT accurately predicts tumor response and survival in hepatocellular carcinoma patients treated with 90Y-loaded glass microspheres: preliminary results.
|
J Nucl Med
|
2012
|
1.39
|
|
16
|
Predictive value of 18F-FDG PET and somatostatin receptor scintigraphy in patients with metastatic endocrine tumors.
|
J Nucl Med
|
2009
|
1.36
|
|
17
|
Intra-arterial rhenium-188 lipiodol in the treatment of inoperable hepatocellular carcinoma: results of an IAEA-sponsored multination study.
|
Int J Radiat Oncol Biol Phys
|
2007
|
1.21
|
|
18
|
Role of the multidisciplinary team in the diagnosis and treatment of hepatocellular carcinoma.
|
Expert Rev Gastroenterol Hepatol
|
2012
|
1.14
|
|
19
|
Acrokeratosis paraneoplastica (Bazex' syndrome) associated with metastatic squamous cell esophageal carcinoma.
|
J Clin Oncol
|
2008
|
1.06
|
|
20
|
Randomized controlled trial of tamoxifen in advanced hepatocellular carcinoma.
|
J Clin Oncol
|
2005
|
1.05
|
|
21
|
Treatment of hepatocellular carcinoma (HCC) with systemic chemotherapy combining epirubicin, cisplatinum and infusional 5-fluorouracil (ECF regimen).
|
Cancer Chemother Pharmacol
|
2002
|
1.03
|
|
22
|
Adenocarcinoid of the appendix vermiformis: complete and persistent remission after chemotherapy (folfox) of a metastatic case.
|
Dig Dis Sci
|
2002
|
0.99
|
|
23
|
Treatment of advanced hepatocellular carcinoma with long-acting octreotide: a phase III multicentre, randomised, double blind placebo-controlled study.
|
Eur J Cancer
|
2009
|
0.99
|
|
24
|
Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study).
|
BMC Cancer
|
2011
|
0.97
|
|
25
|
Complete sustained regression of extensive psoriasis with cetuximab combination chemotherapy.
|
Acta Oncol
|
2004
|
0.97
|
|
26
|
Resection of hepatocellular carcinoma in noncirrhotic liver: analysis of risk factors for survival.
|
J Am Coll Surg
|
2005
|
0.96
|
|
27
|
Volumetric changes after (90)y radioembolization for hepatocellular carcinoma in cirrhosis: an option to portal vein embolization in a preoperative setting?
|
Ann Surg Oncol
|
2013
|
0.96
|
|
28
|
Multidisciplinary strategies to improve treatment outcomes in hepatocellular carcinoma: a European perspective.
|
Eur J Gastroenterol Hepatol
|
2013
|
0.93
|
|
29
|
Chemotherapy for inoperable advanced or metastatic cholangiocarcinoma: retrospective analysis of 78 cases in a single center over four years.
|
Chemotherapy
|
2012
|
0.91
|
|
30
|
Systemic chemotherapy for hepatocellular carcinoma in non-cirrhotic liver: a retrospective study.
|
World J Gastroenterol
|
2009
|
0.88
|
|
31
|
Phase III trial of chemotherapy using 5-fluorouracil and streptozotocin compared with interferon alpha for advanced carcinoid tumors: FNCLCC-FFCD 9710.
|
Endocr Relat Cancer
|
2009
|
0.85
|
|
32
|
Cementoplasty for painful bone metastases: a series of 42 cases.
|
Med Oncol
|
2011
|
0.84
|
|
33
|
Utility of Quantitative Tc-MAA SPECT/CT for yttrium-Labelled Microsphere Treatment Planning: Calculating Vascularized Hepatic Volume and Dosimetric Approach.
|
Int J Mol Imaging
|
2011
|
0.84
|
|
34
|
Usefulness and pitfalls of MAA SPECT/CT in identifying digestive extrahepatic uptake when planning liver radioembolization.
|
Eur J Nucl Med Mol Imaging
|
2012
|
0.84
|
|
35
|
Safety of cisplatin combined with continuous 5-FU versus bolus 5-FU and leucovorin, in metastatic gastrointestinal cancer (FFCD 9404 randomised trial).
|
Anticancer Res
|
2006
|
0.83
|
|
36
|
Dosimetric evaluation and therapeutic response to internal radiation therapy of hepatocarcinomas using iodine-131-labelled lipiodol.
|
Nucl Med Commun
|
2008
|
0.83
|
|
37
|
Impact of radiotherapy in the management of locally advanced extrahepatic cholangiocarcinoma.
|
BMC Cancer
|
2013
|
0.82
|
|
38
|
Relapse factors for ileal neuroendocrine tumours after curative surgery: a retrospective French multicentre study.
|
Dig Liver Dis
|
2011
|
0.82
|
|
39
|
Haemolytic uremic syndrome and gemcitabine: jaundice is not always progression in cholangiocarcinoma.
|
Acta Oncol
|
2012
|
0.82
|
|
40
|
Ex vivo right trisegmentectomy with reconstruction of inferior vena cava and "flop" reimplantation.
|
J Am Coll Surg
|
2002
|
0.82
|
|
41
|
Tonsillar metastasis revealing signet-ring cell carcinoma of the rectum.
|
Gastroenterol Clin Biol
|
2005
|
0.81
|
|
42
|
[Medical treatment of a voluminous tumor of the mesenteric root].
|
Gastroenterol Clin Biol
|
2003
|
0.81
|
|
43
|
International Atomic Energy Agency-sponsored multination study of intra-arterial rhenium-188-labeled lipiodol in the treatment of inoperable hepatocellular carcinoma: results with special emphasis on prognostic value of dosimetric study.
|
Semin Nucl Med
|
2008
|
0.80
|
|
44
|
Intra-arterial injection of iodine-131-labeled lipiodol for treatment of hepatocellular carcinoma.
|
Radiother Oncol
|
2006
|
0.80
|
|
45
|
Increased Lipiodol uptake in hepatocellular carcinoma possibly due to increased membrane fluidity by dexamethasone and tamoxifen.
|
Nucl Med Biol
|
2010
|
0.79
|
|
46
|
Longitudinal quality of life study in patients with metastatic gastric cancer. Analysis modalities and clinical applicability of QoL in randomized phase II trial in a digestive oncology.
|
Gastroenterol Clin Biol
|
2005
|
0.79
|
|
47
|
[Acinous-cell carcinoma of a metastatic pancreas treated by chemotherapy].
|
Gastroenterol Clin Biol
|
2002
|
0.79
|
|
48
|
Acute ischemia of the lower limb during chemotherapy for testicular cancer: A report of two cases.
|
Acta Oncol
|
2009
|
0.79
|
|
49
|
Radiation-induced oesophageal carcinoma after breast carcinoma: a report of five cases including three successfully treated by radiochemotherapy.
|
Acta Oncol
|
2007
|
0.78
|
|
50
|
Management of esophageal carcinoma associated with cirrhosis: a retrospective case-control analysis.
|
J Oncol
|
2009
|
0.78
|
|
51
|
Non-invasive diagnostic criteria for hepatocellular carcinoma: the value of contrast washout at imaging and the death of alpha-fetoprotein.
|
Liver Int
|
2011
|
0.77
|
|
52
|
Prognostic Value of Molecular Subtypes in Pancreatic Cancer.
|
Pancreas
|
2017
|
0.76
|
|
53
|
High-dose irinotecan plus LV5FU2 or simplified LV5FU (HD-FOLFIRI) for patients with untreated metastatic colorectal cancer: a new way to allow resection of liver metastases?
|
Oncology
|
2008
|
0.76
|
|
54
|
Automation of labelling of Lipiodol with high-activity generator-produced 188Re.
|
Appl Radiat Isot
|
2010
|
0.76
|
|
55
|
Cost-effectiveness analysis of first-line chemotherapies in metastatic colorectal cancer. Results of the Fédération Francophone de Cancérologie Digestive (FFCD) 9601 randomized trial.
|
Oncology
|
2007
|
0.76
|
|
56
|
In vitro demonstration of synergy/additivity between (188)rhenium and sorafenib on hepatoma lines: preliminary results.
|
Anticancer Res
|
2013
|
0.76
|
|
57
|
Behavioral disorders secondary to profound hypomagnesemia in a patient given cetuximab for metastatic colorectal cancer hypomagnesemia due to cetuximab treatment.
|
Acta Oncol
|
2006
|
0.76
|
|
58
|
Comparison of preoperative imaging and pathological findings for pancreatic head adenocarcinoma: A retrospective analysis by the Association Française de Chirurgie.
|
Medicine (Baltimore)
|
2017
|
0.75
|
|
59
|
[Glucagonoma: a recent series of 7 cases].
|
Bull Cancer
|
2004
|
0.75
|
|
60
|
New drugs for colorectal cancer (irinotecan, oxaliplatin, raltitrexed) meet expectations in routine practice: a single center's experience before and after their introduction.
|
Int J Gastrointest Cancer
|
2005
|
0.75
|
|
61
|
Solid pancreatic tumors in patients younger than 40 years old--experience of a French comprehensive cancer center.
|
Pancreas
|
2015
|
0.75
|
|
62
|
Changes in resting energy expenditure (REE) as a function of tumor response to sunitinib in a cachexic patient with a metastatic endocrine tumor of the pancreas.
|
Acta Oncol
|
2010
|
0.75
|
|
63
|
[Hemoperitoneum secondary to spontaneous rupture of metastatic liver of a testicular germ cell tumor].
|
Gastroenterol Clin Biol
|
2007
|
0.75
|
|
64
|
Clubbing and hypertrophic osteoarthropathy in two patients taking long-term bevacizumab for metastatic colorectal cancer.
|
J Gastrointest Cancer
|
2011
|
0.75
|
|
65
|
[Management of localized, locally advanced and metastatic pancreatic adenocarcinoma].
|
Rev Prat
|
2015
|
0.75
|
|
66
|
Acute immune hematological complication of oxaliplatin. A series of 3 cases.
|
Tumori
|
2014
|
0.75
|
|
67
|
Impressive efficacy of sorafenib in a patient with an hepatocellular carcinoma and a portal vein thrombosis associated with a metastatic ENT cancer.
|
Med Oncol
|
2010
|
0.75
|